Involvement of monoaminergic systems in the antidepressant-like effect of nobiletin

[1]  M. Prigol,et al.  Antidepressant-like pharmacological profile of 3-(4-fluorophenylselenyl)-2,5-diphenylselenophene: Involvement of serotonergic system , 2010, Neuropharmacology.

[2]  O. Mutlu,et al.  Involvement of serotonin receptor subtypes in the antidepressant-like effect of trim in the rat forced swimming test , 2010, Pharmacology Biochemistry and Behavior.

[3]  M. Popoli,et al.  The pharmacological properties of antidepressants , 2010, International clinical psychopharmacology.

[4]  Feng Han,et al.  Nobiletin improves brain ischemia-induced learning and memory deficits through stimulation of CaMKII and CREB phosphorylation , 2009, Brain Research.

[5]  A. Rodrigues,et al.  Antidepressant-like effect of the extract of Rosmarinus officinalis in mice: Involvement of the monoaminergic system , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[6]  S. Kulkarni,et al.  Current investigational drugs for major depression , 2009 .

[7]  A. Rodrigues,et al.  Ascorbic acid administration produces an antidepressant-like effect: Evidence for the involvement of monoaminergic neurotransmission , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[8]  M. Kaster,et al.  Antidepressant-like effect of the organoselenium compound ebselen in mice: evidence for the involvement of the monoaminergic system. , 2009, European journal of pharmacology.

[9]  G. Telegdy,et al.  Involvement of adrenergic and serotonergic receptors in antidepressant-like effect of urocortin 3 in a modified forced swimming test in mice , 2008, Brain Research Bulletin.

[10]  R. Shin,et al.  Nobiletin, a Citrus Flavonoid, Improves Memory Impairment and Aβ Pathology in a Transgenic Mouse Model of Alzheimer's Disease , 2008, Journal of Pharmacology and Experimental Therapeutics.

[11]  H. Yawo,et al.  Nobiletin, a citrus flavonoid with neurotrophic action, augments protein kinase A-mediated phosphorylation of the AMPA receptor subunit, GluR1, and the postsynaptic receptor response to glutamate in murine hippocampus. , 2008, European journal of pharmacology.

[12]  D. Nutt.  Relationship of neurotransmitters to the symptoms of major depressive disorder. , 2008, The Journal of clinical psychiatry.

[13]  Si-young Song,et al.  Nobiletin, a citrus flavonoid that improves memory impairment, rescues bulbectomy-induced cholinergic neurodegeneration in mice. , 2007, Journal of pharmacological sciences.

[14]  J. Richardson,et al.  Complementary medicine for depression , 2006, Expert review of neurotherapeutics.

[15]  Y. Ohizumi,et al.  Nobiletin restoring β-amyloid-impaired CREB phosphorylation rescues memory deterioration in Alzheimer's disease model rats , 2006, Neuroscience Letters.

[16]  M. Millan.  Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. , 2006, Pharmacology & therapeutics.

[17]  Eric J. Nestler,et al.  New approaches to antidepressant drug discovery: beyond monoamines , 2006, Nature Reviews Neuroscience.

[18]  E. Esposito.  Serotonin-dopamine interaction as a focus of novel antidepressant drugs. , 2006, Current drug targets.

[19]  Y. Ohizumi,et al.  Nobiletin and its related flavonoids with CRE-dependent transcription-stimulating and neuritegenic activities. , 2005, Biochemical and biophysical research communications.

[20]  Michael Rickels,et al.  Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants , 1995, Psychopharmacology.

[21]  M. Detke,et al.  Blockade of the antidepressant-like effects of 8-OH-DPAT, buspirone and desipramine in the rat forced swim test by 5HT1A receptor antagonists , 1995, Psychopharmacology.

[22]  S. Gershon,et al.  Dopamine and depression , 2005, Journal of Neural Transmission / General Section JNT.

[23]  Michel Bourin,et al.  Dopamine, depression and antidepressants , 2004, Fundamental & clinical pharmacology.

[24]  S. Yamada,et al.  Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test. , 2004, European journal of pharmacology.

[25]  A. S. Elhwuegi.  Central monoamines and their role in major depression , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[26]  B. Thierry,et al.  The tail suspension test: A new method for screening antidepressants in mice , 2004, Psychopharmacology.

[27]  T. Nakazawa,et al.  Antidepressant-like effects of apigenin and 2,4,5-trimethoxycinnamic acid from Perilla frutescens in the forced swimming test. , 2003, Biological & pharmaceutical bulletin.

[28]  V. Klimek,et al.  Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study , 2002, Biological Psychiatry.

[29]  R. Bressan,et al.  Typical antipsychotic drugs — D2 receptor occupancy and depressive symptoms in schizophrenia , 2002, Schizophrenia Research.

[30]  G. Nowak,et al.  Effect of imipramine on brain D-1 and 5-HT-2A receptors in a chronic unpredictable stress model in rats. , 2002, Polish journal of pharmacology.

[31]  P. Skolnick,et al.  Intra- and interstrain differences in models of “behavioral despair” , 2001, Pharmacology Biochemistry and Behavior.

[32]  M. Bourin,et al.  Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test? , 2001, European Neuropsychopharmacology.

[33]  I. Lucki,et al.  Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice. , 2001, The Journal of pharmacology and experimental therapeutics.

[34]  L. San,et al.  Altered 5-HT2A binding sites and second messenger inositol trisphosphate (IP3) levels in hippocampus but not in frontal cortex from depressed suicide victims , 2000, Psychiatry Research: Neuroimaging.

[35]  H. Ågren,et al.  Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. , 2000, Archives of general psychiatry.

[36]  P. Delgado.  Depression: the case for a monoamine deficiency. , 2000, The Journal of clinical psychiatry.

[37]  D. Dlaboga,et al.  Pharmacological effects of milnacipran, a new antidepressant, given repeatedly on the α1-adrenergic and serotonergic 5-HT2A systems , 2000, Journal of Neural Transmission.

[38]  A. Fugh-Berman,et al.  Dietary supplements and natural products as psychotherapeutic agents. , 1999, Psychosomatic medicine.

[39]  G. Fillion,et al.  5-Hydroxytryptamine-moduline: a novel endogenous peptide involved in the control of anxiety , 1999, Neuroscience.

[40]  P. Delgado,et al.  Antidepressants and the brain. , 1999, International clinical psychopharmacology.

[41]  J. Guimón,et al.  Up‐Regulation of Immunolabeled α2A‐Adrenoceptors, Gi Coupling Proteins, and Regulatory Receptor Kinases in the Prefrontal Cortex of Depressed Suicides , 1999, Journal of neurochemistry.

[42]  D. Sibley,et al.  New insights into dopaminergic receptor function using antisense and genetically altered animals. , 1999, Annual review of pharmacology and toxicology.

[43]  P. Willner.  The mesolimbic dopamine system as a target for rapid antidepressant action , 1997, International clinical psychopharmacology.

[44]  B. Leonard.  Noradrenaline in basic models of depression , 1997, European Neuropsychopharmacology.

[45]  S. Stahl,et al.  Book Review: Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 2nd Edition , 1996 .

[46]  J. Costentin,et al.  Indirect dopamine agonists effects on despair test: Dissociation from hyperactivity , 1996, Pharmacology Biochemistry and Behavior.

[47]  D. Charney,et al.  The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. , 1996, Pharmacopsychiatry.

[48]  K. Yamamoto,et al.  Pharmacological profile of gastric mucosal protection by marmin and nobiletin from a traditional herbal medicine, Aurantii fructus immaturus. , 1994, Japanese journal of pharmacology.

[49]  A. Heinz,et al.  Anhedonia in Schizophrenic, Depressed, or Alcohol-Dependent Patients - Neurobiological Correlates , 1994, Pharmacopsychiatry.

[50]  G. Baker,et al.  5‐Hydroxytryptamine2 and β‐Adrenergic Receptor Regulation in Rat Brain Following Chronic Treatment with Desipramine and Fluoxetine Alone and in Combination , 1994, Journal of neurochemistry.

[51]  C. Katona,et al.  Brain β-adrenoceptor binding sites in antidepressant-free depressed suicide victims , 1990, Brain Research.

[52]  I. Ferrier,et al.  5HT2 receptor changes in major depression , 1990, Biological Psychiatry.

[53]  Enhanced functional responsiveness of the dopaminergic system—the mechanism of anti-immobility effects of antidepressants in the behavioural despair test in the rat , 1988, Neuropharmacology.

[54]  B. Thierry,et al.  The automated tail suspension test: A computerized device which differentiates psychotropic drugs , 1987, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[55]  L. Singh,et al.  Chronic antidepressant treatment reduces central β-adrenoceptor sensitivity in a behavioral test , 1986 .

[56]  V. Klimek,et al.  Antidepressant drugs given repeatedly increase binding to α1-adrenoceptors in the rat cortex , 1985 .

[57]  R. Porsolt,et al.  Behavioral despair in mice: a primary screening test for antidepressants. , 1977, Archives internationales de pharmacodynamie et de therapie.